$14.48−0.05 (−0.34%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Mineralys Therapeutics (MLYS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+87.0%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY22–FY25
Revenue ($M)—
0.0
FY22→FY25CAGR —
Net income ($M)▲13.0%
−154.7
FY22→FY25CAGR —
Free cash flow ($M)▲14.4%
−142.4
no value for 1 of 4 yearsCAGR —
Diluted EPS▲37.4%
−2.29
FY22→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+87.0%
36.2mn → 67.7mn diluted shares since FY23. Rising share count dilutes EPS. Growth must outrun it.
Capex
$15.0K
−84.4% YoY in FY25.
Returns vs FCF
n/m
$0.4M returned vs $−142.4M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
What the income statement says · FY22–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY22–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7603, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | YoY | CAGR 22→25 |
|---|---|---|---|---|---|---|---|
| Revenue & profitability | |||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 292.8 | 132.0 | 168.6 | 70.4 | 26.3 | ▼21.7% | +71.3% |
Selling, general & admin | 96.9 | 38.6 | 23.8 | 14.3 | 5.2 | ▲62.0% | +94.7% |
Total operating expenses | 389.7 | 170.6 | 192.4 | 84.7 | 31.5 | ▼11.3% | +75.7% |
Operating incomefeeds ROC rank | −389.7 | −170.6 | −192.4 | −84.7 | −31.5 | ▲11.3% | — |
Other income, net | 19.8 | 16.0 | 14.6 | 12.8 | 1.7 | — | — |
Pretax income | −370.0 | −154.7 | −177.8 | −71.9 | −29.8 | ▲13.0% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −370.0 | −154.7 | −177.8 | −71.9 | −29.8 | ▲13.0% | — |
| Per share | |||||||
Diluted EPSbuyback-sensitive | −4.28 | −2.29 | −3.66 | −1.99 | −5.77 | ▲37.4% | — |
Diluted shares (mn) | 88.99 | 67.66 | 48.54 | 36.19 | 5.17 | ▲39.4% | +135.7% |
| Margins | |||||||
† TTM = trailing four quarters through 2026-09-30.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

